A Phase Iii, Randomized, Open-Label Study Of First-Line Durvalumab (D) With Or Without Tremelimumab (T) Vs Standard Of Care Chemotherapy In Patients With Unresectable, Locally Advanced Or Metastatic Urothelial Carcinoma (Danube)
Annals of Oncology(2020)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要